to its abolition during intravenous tocainide administration. It seems likely that acceleration of VT rate was induced by tocainide, since in both of our patients their episodic VT had been at constant frequency during observation for 1 month. Although both of these patients had severe underlying heart disease with chronic potentially life-threatening recurrent VT, VF occurred only once in each individual and in each instance in close proximity to initiation of tocainide therapy. Furthermore, VF has not reoccurred since tocainide was discontinued.
There were no apparent metabolic or electrolyte abnormalities which might have explained their worsening of ventricular tachyarrhythmias during tocainide. Other antiarrhythmic drugs had been discontinued sufficiently prior to VF to make such change in therapy an important factor. Serum digoxin concentrations were at levels unlikely to be associated with toxic arrhythmias.
While a potential interaction between tocainide and digoxin might have resulted in VF, such an event has not been observed with lidocaine, a drug with similar structure and electrophysiologic effects as tocainide. While it ;S not possible to exclude the causal relation of their severe underlying cardiac disease processes or disturbed pharmacokinetics due to related organ system dysfunction, it is not unreasonable to suspect that tocainide was responsible for initiation of VF in these two patients.
Unfortunately, tocainide blood levels were not available in both patients. Tocainide is principally removed (45%) by excretion in the urine in unchanged form and 23% is metabolized by carboxylation in the liver. Since our first patient had severe congestive heart failure, impaired excretion might have resulted in toxic blood levels. However, our second patient had normal renal and hepatic function. Based on previous experience with the pharmacokinetics of this highly bioavailable oral drug,', 6 it is quite unlikely that our second patient had toxic serum levels. Furthermore, signs and symptoms of CNS or gastrointestinal toxicity were absent in both patients, and these side effects usually occur with high tocainide blood levels.',6 Based on these two untoward experiences, we now believe that it is prudent to initiate tocainide therapy in a monitored hospital setting. localizing the origin of the bypass tract on the right side (Fig. 3) , and in defining the risk of rapid ventricular rates should atria1 flutter or fibrillation deve1op.j. . Diagram A shows the lordotic view of the heart (the view is as if one is looking at the heart from the diaphragm). The "Ebstein-like" pouch projects inferiorly from the diaphragmatic surface; this tissue generated a ventricular electrogram but communicated with the right atrium, not the right ventricular cavity above it. The dotted line indicates the site of the epicardial incision. In Diagram B, the right coronary fat pad was dissected away from the atrioventricular groove through an incision in the epicardium extending from the insertion of the inferior vena cava to the crux of the heart posteriorly. By sharp and blunt dissection under the eleva.ted fat pad the atrium was separated from the ventricle along this entire Rength, exposing the roof of the coronary sinus and posterior portion of the ventricular septum. A through-and-through incision was then made in the atrialized ventricle at the point of separation from the ventricular septum and coronary sinus to insure complete division of al.1 fibers between the atrium and ventricle. The epicardial and endocardial incisions were then closed. Diagrams C through F illustrates the modified Fontan technique. The pulmonary valve was normal in size; therefore it was incorporated into the repair. 'The atria1 septal defect was closed with a Dacron patch. A 5 cm longitudinal incision was made in the right ventricular infundibulum.
A 5-by 5-cm flap of right atria1 appendage was folded back and sutured to the right edge of the ventriculotomy to form the floor of the conduit (Diagrams C and 0). Then a 7-by-9 cm rectangle of pericardium was sutured to the edge of the atria1 flap, and to the left edge of the ventriculotomy to constitute the roof of the conduit (Diagrams E and F). Upon completion of the procedure, the patient was in sinus rhythm without anomalous atrioventricular conduction (Fig. 1 , right-hand panel).
conduction was explained by finding a delay in intra-atrial conduction (PA interval 53 msec). Finally, the antegrade effective refractory period in the anomalous pathway of greater than 450 msec (sinus cycle length 740 msec) reduced the risk of the initiation of either ventricular tachycardia or ventricular fibrillation. The finding of the Ebstein-like defect at surgery (Fig.  5,A) the Ebstein type of tricuspid atresia,' whereas the pathophysiology, dependent upon the associated lesions, fits Edward's type 1B.l Despite the "Ebstein-like" anatomy, severe hypoplasia of the right ventricle necessitated the Fontan operation. (Figs. 5,C to F) . The surgical approach to the identification (Fig. 4) and division (Fig. 5,B ) of the bypass tract was similar to previously described techniques in patients with posterior right-sided pathways with Ebstein's anomaly." The epicardial mapping procedure yielded precise localization of the accessory pathway (Fig. 4) In 1957 Jervell and Lange-Nielsen' jointly reported the peculiar syndrome of QT prolongation with deafness. The syndrome without deafness has been termed the RomanoWard syndrome. Syncopal episodes in these syndromes have been documented to be due to ventricular fibrillation' or less frequently to ventricular asystole." In the Romano-Ward syndrome, the QT interval prolongation represents a stable feature, while T wave alternans is episodic and appears related to changes in activity of the sympathetic nervous system.' In our patient T wave alternans was present at slower heart rates, but when the heart rate was increased by a vagolytic agent, T wave alternans disappeared. Similar findings have been reported by Lopez et al." The presence of intermittent atrioventricular block is also an unusual feature in our case. This finding is consistent with the patient reported by Crawford et al.," in whom atrioventricular nodal disease was progressive.
No consistently effective therapy is available. Although propranolol is considered to be the most effective drug for preventing ventricular tachyarrhythmias, the agent is unsafe in the presence of atrioventricular nodal disease because of its action of depressing atrioventricular conduction. Phenytoin (diphenylhydantoin) has been successfully employed, as in our patient, because of the agent's inhibitory effect on central nervous system dis-
